All In Biotech

Drug Trial Radar · NCT07477587

A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

A Randomized, Double-blind, Parallel-controlled Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 258 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

258

Planned (sponsor's estimate)

Start

May 25, 2026

Primary completion

May 25, 2027

Study completion Feb 22, 2028

Sponsor

Lead sponsor
Shanghai Henlius BiotechIndustry
Sponsor type
Industry
First posted
Mar 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the pharmacokinetic (PK) similarity, safety, tolerability, immunogenicity, and efficacy of HLX15-SC versus US-DARZALEX FASPRO® following single and multiple subcutaneous (SC) injections in newly diagnosed MM patients ineligible for transplant. Participants who meet all inclusion criteria and none of the exclusion criteria will receive either the HLX15-SC-Rd regimen or the D-Rd regimen for 4 cycles (one cycle = 4 weeks). After 4 cycles of treatment, based on clinical benefit and participant preference, participants may continue to receive the locally marketed daratumumab subcutaneous formulation (Dara-SC) in combination with Rd according to clinical practice, up to 32 weeks or until loss of clinical benefit, death, unacceptable toxicity, withdrawal of informed consent, or any other protocol-specified reason, whichever occurs first. After 32 weeks of dosing, participants will continue to receive appropriate standard of care according to local guidelines (including marketed Dara-SC).

Conditions

  • Multiple Myeloma (MM)

Interventions

  • HLX15-SC-RdDrug

    Subjects will receive 1800 mg HLX15-SC via SC administration for up to 16 weeks: weekly during Week 1-8 (Cycle 1-2; 1 cycle = 4 weeks) and every two weeks during Week 9-16 (Cycle 3-4).

  • US-DARZALEX FASPRO®-RdDrug

    Subjects will receive 1800 mg US-DARZALEX FASPRO® via SC administration for up to 16 weeks: weekly during Week 1-8 (Cycle 1-2; 1 cycle = 4 weeks) and every two weeks during Week 9-16 (Cycle 3-4).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. pharmacokinetic (PK) similarityTime frame: 7 days
  2. pharmacokinetic (PK) similarityTime frame: 7 days
  3. pharmacokinetic (PK) similarityTime frame: 16 weeks
  4. pharmacokinetic (PK) similarityTime frame: 16 weeks

Locations

84 sites in 5 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group, PA

    Springdale, Arkansas · Recruiting

  • Cancer Specialists of North Florida

    Jacksonville, Florida · Recruiting

  • D&H National Research Center

    Margate, Florida · Recruiting

  • Ocala Oncology Center

    Ocala, Florida · Recruiting

  • Florida Clinical Trials Group

    Plantation, Florida · Recruiting

  • Florida Clinical Trials Group

    Tamarac, Florida · Recruiting

  • Genesis Medical Research

    Dyer, Indiana · Recruiting

  • Pontchartrain Cancer Center

    Covington, Louisiana · Recruiting

  • Oncology Consultants (P1 Trials -Exigent Network)

    Houston, Texas · Recruiting

  • Lumi Research

    Houston, Texas · Recruiting

  • Optum Care Washington

    Everett, Washington · Recruiting

  • American Oncology Network Vista Oncology Division / Physician partner associate

    Olympia, Washington · Recruiting

  • Perth Blood Institute

    Perth, Australia · Recruiting

  • The First Affiliated Hospital of Bengbu Medical University

    Bengbu, Anhui, China · Recruiting

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, China · Recruiting

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China · Recruiting

  • Beijing Chao-Yang Hospital Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • Peking University First Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Recruiting

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China · Recruiting

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China · Recruiting

  • Guangzhou First People's Hospital

    Guangzhou, Guangdong, China · Recruiting

  • Guangdong General Hospital

    Guangzhou, Guangdong, China · Recruiting

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, China · Recruiting

  • Meizhou People's Hospital

    Meizhou, Guangdong, China · Recruiting

  • Shenzhen People's Hospital

    Shenzhen, Guangdong, China · Recruiting

  • Peking University Shenzhen Hospital

    Shenzhen, Guangdong, China · Recruiting

  • Liuzhou Worker's Hospital

    Liuzhou, Guangxi, China · Recruiting

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi, China · Recruiting

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China · Recruiting

  • Affiliated Hospital of Hebei University

    Baoding, Hebei, China · Recruiting

  • Cangzhou People's Hospital

    Cangzhou, Hebei, China · Recruiting

  • Hebei medical university third hospital

    Shijiazhuang, Hebei, China · Recruiting

  • The Second Hospital of Hebei Medical Universit

    Shijiazhuang, Hebei, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Recruiting

  • The First Affiliated Hospital of Henan University of Science & Techinology

    Luoyang, Henan, China · Recruiting

  • Xinxiang Central Hospital

    Xinxiang, Henan, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China · Recruiting

Showing 40 of 84 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.